Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ003234 (Plonmarlimab) in Rheumatoid Arthritis
NCT04457856Phase 1Unknown
- Sponsor
- I-Mab
- Start
- Aug 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing TJ003234 (Plonmarlimab) with Placebo (2 arms). Primary endpoint: Number of subject with adverse events (AEs) at 140 days. Status: unknown.
02
Drugs
plonmarlimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04457856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457856.